Theralase Technologies Inc. (TLTFF)
TLTFF Stock Price Chart
Explore Theralase Technologies Inc. interactive price chart. Choose custom timeframes to analyze TLTFF price movements and trends.
TLTFF Company Profile
Discover essential business fundamentals and corporate details for Theralase Technologies Inc. (TLTFF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
5 Apr 2010
Employees
14.00
Website
https://www.theralase.comCEO
Roger John Dumoulin-White
Description
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.
TLTFF Financial Timeline
Browse a chronological timeline of Theralase Technologies Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 May 2026
Upcoming earnings on 10 Mar 2026
Upcoming earnings on 27 Nov 2025
Revenue estimate is $230.00K.
Earnings released on 26 Aug 2025
EPS came in at -$0.00 falling short of the estimated -$0.00 by -33.64%, while revenue for the quarter reached $161.40K , missing expectations by -29.83%.
Earnings released on 30 May 2025
EPS came in at -$0.00 falling short of the estimated -$0.00 by -100.48%, while revenue for the quarter reached $64.03K , missing expectations by -67.98%.
Earnings released on 12 Mar 2025
EPS came in at -$0.00 falling short of the estimated -$0.00 by -27.88%, while revenue for the quarter reached $285.22K , beating expectations by +0.11%.
Earnings released on 27 Nov 2024
EPS came in at -$0.00 falling short of the estimated -$0.00 by -49.00%, while revenue for the quarter reached $255.39K , beating expectations by +70.26%.
Earnings released on 12 Aug 2024
EPS came in at -$0.00 falling short of the estimated -$0.00 by -48.55%, while revenue for the quarter reached $73.76K , beating expectations by +0.15%.
Earnings released on 30 May 2024
EPS came in at -$0.00 , while revenue for the quarter reached $129.28K .
Earnings released on 27 Mar 2024
EPS came in at -$0.00 , while revenue for the quarter reached $273.77K , missing expectations by -0.32%.
Earnings released on 29 Nov 2023
EPS came in at -$0.00 surpassing the estimated -$0.01 by +53.26%, while revenue for the quarter reached $207.17K , missing expectations by -2.95%.
Earnings released on 29 Aug 2023
EPS came in at -$0.00 surpassing the estimated -$0.01 by +46.55%, while revenue for the quarter reached $165.26K , missing expectations by -24.46%.
Earnings released on 30 May 2023
EPS came in at -$0.00 surpassing the estimated -$0.01 by +34.91%, while revenue for the quarter reached $153.10K .
Earnings released on 31 Dec 2022
EPS came in at -$0.00 , while revenue for the quarter reached $242.64K , beating expectations by +0.89%.
Earnings released on 29 Nov 2022
EPS came in at -$0.01 falling short of the estimated -$0.01 by -40.06%, while revenue for the quarter reached $190.27K , beating expectations by +31.65%.
Earnings released on 29 Aug 2022
EPS came in at -$0.01 falling short of the estimated -$0.01 by -40.06%, while revenue for the quarter reached $264.57K , missing expectations by -0.08%.
Earnings released on 30 May 2022
EPS came in at -$0.01 surpassing the estimated -$0.01 by +16.65%, while revenue for the quarter reached $169.30K , missing expectations by -0.08%.
Earnings released on 29 Apr 2022
EPS came in at -$0.01 falling short of the estimated -$0.01 by -49.93%, while revenue for the quarter reached $167.69K .
Earnings released on 29 Nov 2021
EPS came in at -$0.01 matching the estimated -$0.01, while revenue for the quarter reached $107.92K .
Earnings released on 30 Aug 2021
EPS came in at -$0.01 falling short of the estimated -$0.01 by -40.06%, while revenue for the quarter reached $246.24K .
Earnings released on 28 May 2021
EPS came in at -$0.00 falling short of the estimated -$0.00 by -100.00%, while revenue for the quarter reached $99.28K .
Earnings released on 28 Apr 2021
EPS came in at -$0.00 falling short of the estimated -$0.00 by -59.91%, while revenue for the quarter reached $314.63K .
Earnings released on 27 Nov 2020
EPS came in at -$0.01 matching the estimated -$0.01, while revenue for the quarter reached $175.78K .
TLTFF Stock Performance
Access detailed TLTFF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.